A growing body of evidence suggests that a small subset of patients using GLP-1 receptor agonists like Ozempic and Wegovy may develop a rare but serious brain condition linked to their treatment. Early studies indicate the disorder could involve neurological symptoms, though the exact mechanisms and long-term risks remain under investigation. Health authorities are reviewing the findings as regulators weigh whether updated safety warnings are necessary. The discovery raises questions about the balance between these drugs’ benefits for weight management and diabetes and their potential neurological side effects.
Researchers found a rare but potentially life-threatening brain disorder in a small number of people taking Ozempic, Wegovy and similar drugs.
